Seluna Raises €752K And Launches Major Clinical Trial For Childhood Sleep Disorder Diagnostics

Alongside the funding, the company has launched an NHS validation study aimed at addressing the widespread underdiagnosis of paediatric sleep apnoea.

The funding round was led by Gabriel Investment Syndicate, with additional support from Scottish Enterprise, the University of Strathclyde, and new investor STAC Invest.

"Paediatric sleep diagnostics has been underserved for too long. It’s a complex challenge, which is why existing tools weren’t built for children until now. This validation study will demonstrate clinical impact and make a clear statement: we’re here to set a new standard. We’re here to innovate, drive change, and compete internationally, with backing from investors who recognise the potential of the paediatric healthcare market," said Dr Scott Black, Co-founder and CEO of Seluna.

Founded in 2022 by Dr. Black and Dr. Yola Jones, Seluna was born out of concerns from paediatric clinicians about delays in diagnosing children with sleep-related breathing disorders.

To address this, the team developed an AI-driven tool that detects and classifies digital biomarkers from sleep study data, providing clear and interpretable insights to support rather than replace clinical decisions.

Seluna’s technology aims to transform the diagnosis and management of a condition affecting an estimated 96 million children worldwide, 80% of whom remain undiagnosed.

"What makes Seluna’s approach so compelling is its focus on explainable AI. As clinicians, we need to understand why the technology is making certain recommendations. Seluna’s focus on interpretability builds the trust we need to confidently use this technology in clinical practice. It will help take pressure off busy departments and allow us to stop firefighting wait lists," said Dr Ruth Hamilton, Consultant Clinical Scientist at the Royal Hospital for Children and principal investigator for the trial.

A 500-patient study at the Royal Hospital for Children in Glasgow will validate Seluna’s proprietary Software as a Medical Device (SaMD). The software uses a series of machine learning algorithms to automatically analyse sleep study data a task that typically requires time-consuming manual review by clinicians.

This is the first machine learning-based SaMD built specifically for diagnosing sleep disorders in children, addressing a long-standing gap in a field that has largely focused on adult patients.

"Seluna is developing a solution which could dramatically improve our ability to identify and prioritise the children who need help most urgently. It has the potential to transform how we approach paediatric sleep medicine." noted Dr Haytham Kubba, Paediatric ENT Surgeon at the Royal Hospital for Children and chief investigator on the study.

Beyond diagnosis, Seluna aims to fill a critical gap in clinical decision-making by helping identify which children will truly benefit from treatment. Currently, the most common intervention is adenotonsillectomy removal of the tonsils and adenoids but many children undergo this surgery unnecessarily, due to a lack of detailed physiological insight.

"Seluna represents exactly the kind of investment opportunity STAC Invest is looking for a world-class founding team tackling a significant global challenge with genuinely innovative technology," said Angus Macfadyen, Head of Investment at STAC.

This marks the first phase of a broader, multi-site validation effort, with additional NHS centres set to join by the end of the year. The goal is to build a more diverse, UK-wide dataset and reduce bias in model development.

Seluna is targeting UK Class I medical device certification by the end of 2026, with plans to secure US FDA Class II approval by 2027.

Meanwhile, Alex Lusty of Gabriel Investment Syndicate commented: "Gabriel was delighted to lead this second round investment into Seluna, recognising the company’s exceptional progress in building the product, commercial partnerships and internal team capability. It’s been great to see the strong clinical engagement with the company’s ethical AI-based diagnostic pathway. We look forward to continuing to support Seluna as the company transitions to helping children in the UK and US."

About Seluna

Seluna is a MedTech startup transforming pediatric sleep apnea care with the first auto-scoring software specifically designed for children. Designed with clinicians in the UK and US, our AI-driven tool speeds up sleep study analysis, improves diagnosis accuracy, supports treatment decisions, and integrates seamlessly into clinical workflows.